MRNA Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 20.83%. Moderna, Inc.'s return on equity of -29.19% beat Johnson & Johnson's return on equity of 34.46%.

Moderna, Inc. has a consensus price target of $42.25, signalling downside risk potential of -26.9%. On the other hand Johnson & Johnson has an analysts' consensus of $233.13 which suggests that it could fall by -4.96%. Given that Moderna, Inc. has more downside risk than Johnson & Johnson, analysts believe Johnson & Johnson is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.291, which suggesting that the stock is 29.087% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.12% to investors and pays a quarterly dividend of $1.30 per share. Moderna, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Moderna, Inc.'s net income of -$826M is lower than Johnson & Johnson's net income of $5.1B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 22.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 11.57x versus 6.32x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 34.4%. Moderna, Inc.'s return on equity of -29.19% beat Eli Lilly & Co.'s return on equity of 104.39%.

Moderna, Inc. has a consensus price target of $42.25, signalling downside risk potential of -26.9%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 21%. Given that Eli Lilly & Co. has higher upside potential than Moderna, Inc., analysts believe Eli Lilly & Co. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.291, which suggesting that the stock is 29.087% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Moderna, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Moderna, Inc.'s net income of -$826M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 44.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 11.57x versus 14.03x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of 18.15%. Moderna, Inc.'s return on equity of -29.19% beat Merck & Co., Inc.'s return on equity of 36.76%.

Moderna, Inc. has a consensus price target of $42.25, signalling downside risk potential of -26.9%. On the other hand Merck & Co., Inc. has an analysts' consensus of $127.46 which suggests that it could grow by 5.97%. Given that Merck & Co., Inc. has higher upside potential than Moderna, Inc., analysts believe Merck & Co., Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.291, which suggesting that the stock is 29.087% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.269, suggesting its less volatile than the S&P 500 by 73.077%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.73% to investors and pays a quarterly dividend of $0.85 per share. Moderna, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Moderna, Inc.'s net income of -$826M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 11.57x versus 4.65x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -121.83% compared to Moderna, Inc.'s net margin of -9.34%. Moderna, Inc.'s return on equity of -29.19% beat Pfizer Inc.'s return on equity of 8.69%.

Moderna, Inc. has a consensus price target of $42.25, signalling downside risk potential of -26.9%. On the other hand Pfizer Inc. has an analysts' consensus of $28.43 which suggests that it could grow by 6.78%. Given that Pfizer Inc. has higher upside potential than Moderna, Inc., analysts believe Pfizer Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.291, which suggesting that the stock is 29.087% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.474, suggesting its less volatile than the S&P 500 by 52.65%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.46% to investors and pays a quarterly dividend of $0.43 per share. Moderna, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.85% of its earnings as a dividend.

Moderna, Inc. quarterly revenues are $678M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Moderna, Inc.'s net income of -$826M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 19.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 11.57x versus 2.43x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.